Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 38Melanoma 36Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 10Pancreatic Neoplasms 5Neoplasm Metastasis 4Glioma 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Leukemia, Myeloid, Acute 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colonic Neoplasms 2Brain Neoplasms 2Astrocytoma 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × trametinib × Clear all
NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
117 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡